Go Pro
NASDAQ:TRIB

Trinity Biotech Q1 2026 Earnings Report

Trinity Biotech logo
$6.32 -0.11 (-1.71%)
Closing price 10/1/2026 03:47 PM Eastern
Extended Trading
$6.32 0.00 (-0.02%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Trinity Biotech EPS Results

Actual EPS
-$6.90
Consensus EPS
-$9.30
Beat/Miss
Beat by +$2.40
One Year Ago EPS
N/A

Trinity Biotech Revenue Results

Actual Revenue
$10.85 million
Expected Revenue
$10.68 million
Beat/Miss
Beat by +$168.00 thousand
YoY Revenue Growth
N/A

Trinity Biotech Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Thursday, June 18, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Trinity Biotech's Q2 2026 earnings is estimated for Thursday, December 10, 2026, based on past reporting schedules

Earnings Documents

Trinity Biotech Earnings Headlines

They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, and Millennium by 122%. Kopernik Global made it their largest holding, owning roughly 8% of the company. It holds rights to an 88 million ounce deposit with existing roads, power, and permits that never expire. Market cap sits near $4 billion against a deposit worth hundreds of billions at current gold prices.tc pixel
See More Trinity Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Trinity Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trinity Biotech and other key companies, straight to your email.

About Trinity Biotech

Trinity Biotech (NASDAQ:TRIB) is a biotechnology and medical diagnostics company headquartered in Ireland. The company develops, manufactures and markets diagnostic products used by clinical laboratories, healthcare providers and other testing facilities. Its offerings are designed to support the detection and management of infectious diseases, autoimmune conditions and other medical disorders.

Trinity Biotech’s portfolio has historically included point-of-care and laboratory-based tests for conditions such as HIV, hepatitis, syphilis and autoimmune diseases. The company has also provided clinical laboratory services and diagnostic technologies, serving healthcare markets in North America, Europe and other international regions through direct operations, distributors and strategic relationships.

Founded in 1992, Trinity Biotech has expanded through internal development and acquisitions of diagnostic businesses and technologies. Its products are used in a range of settings, including hospitals, reference laboratories, physician offices, public-health programs and resource-limited environments where rapid testing can be important.

View Trinity Biotech Profile